Form 8-K - Current report:
SEC Accession No. 0001437749-22-001921
Filing Date
2022-01-31
Accepted
2022-01-31 07:05:15
Documents
15
Period of Report
2022-01-31
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K arav20220128_8k.htm   iXBRL 8-K 28438
2 EXHIBIT 99.1 ex_329267.htm EX-99.1 12303
7 logo.jpg GRAPHIC 2219
  Complete submission text file 0001437749-22-001921.txt   184695

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA arav-20220131.xsd EX-101.SCH 3594
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE arav-20220131_def.xml EX-101.DEF 11808
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE arav-20220131_lab.xml EX-101.LAB 15859
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arav-20220131_pre.xml EX-101.PRE 12023
9 EXTRACTED XBRL INSTANCE DOCUMENT arav20220128_8k_htm.xml XML 2682
Mailing Address RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098
Business Address RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098 936-355-1910
Aravive, Inc. (Filer) CIK: 0001513818 (see all company filings)

EIN.: 264106690 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36361 | Film No.: 22571179
SIC: 2834 Pharmaceutical Preparations